NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT)

Phase 2

Completed

Conditions: Cardiovascular Disease
Chronic Kidney Disease
Death

Interventions: Drug: High Dose Multivitamin
Device: Low Dose Multivitamin

First Posted Date: 2003-07-15

Last Posted Date: 2017-10-18

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 4110

Registration Number: NCT00064753

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Cedars-Sinai Health System/Center for Kidney Diseases and Transplantation, Los Angeles, California, United States
🇺🇸
University of California at Los Angeles, Los Angeles, California, United States

and more 27 locations

Radiation Therapy and the Natural History of Childhood Cancers

Completed

Conditions: Childhood Malignancy
Cancer

First Posted Date: 2003-07-15

Last Posted Date: 2020-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 241

Registration Number: NCT00064883

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Minimally Invasive Surgical Therapy for BPH

Phase 3

Terminated

Conditions: Benign Prostatic Hyperplasia

Interventions: Device: Transurethral Needle Ablation (TUNA) Therapy
Drug: Finasteride and Alfuzosin
Device: Transurethral Microwave Thermotherapy (TUMT)

First Posted Date: 2003-07-11

Last Posted Date: 2010-01-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 49

Registration Number: NCT00064649

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 4 locations

Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma

Phase 3

Completed

Conditions: AIDS-related Kaposi Sarcoma

Interventions: Drug: pegylated liposomal doxorubicin hydrochloride
Drug: paclitaxel
Other: laboratory biomarker analysis
Procedure: quality-of-life assessment

First Posted Date: 2003-07-11

Last Posted Date: 2013-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 240

Registration Number: NCT00003350

Locations: 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Phase 1

Completed

Conditions: Childhood Central Nervous System Germ Cell Tumor
Childhood Choroid Plexus Tumor
Childhood Craniopharyngioma
Childhood Ependymoblastoma
Childhood Grade I Meningioma
Childhood Grade II Meningioma
Childhood Grade III Meningioma
Childhood High-grade Cerebellar Astrocytoma
Childhood High-grade Cerebral Astrocytoma
Childhood Infratentorial Ependymoma

Interventions: Drug: cilengitide
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00063973

Locations: 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

Phase 2

Completed

Conditions: Recurrent Kaposi Sarcoma
AIDS-related Kaposi Sarcoma

Interventions: Other: placebo
Drug: halofuginone hydrobromide
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-07-09

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT00064142

Locations: 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Phase 1

Terminated

Conditions: Stage IIIC Breast Cancer
Male Breast Cancer
Stage IIIB Breast Cancer
Stage IIIA Breast Cancer
Stage IV Breast Cancer

Interventions: Biological: oblimersen sodium
Drug: doxorubicin hydrochloride
Drug: docetaxel
Biological: filgrastim
Biological: pegfilgrastim
Procedure: therapeutic conventional surgery
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2019-03-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00063934

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage III Squamous Cell Carcinoma of the Larynx
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IV Ovarian Epithelial Cancer
Stage IV Squamous Cell Carcinoma of the Hypopharynx
Stage IVA Squamous Cell Carcinoma of the Larynx
Stage IVA Squamous Cell Carcinoma of the Oropharynx
Stage IVC Squamous Cell Carcinoma of the Larynx
Recurrent Squamous Cell Carcinoma of the Nasopharynx
Stage III Squamous Cell Carcinoma of the Nasopharynx

Interventions: Drug: erlotinib hydrochloride
Other: pharmacological study
Other: pharmacogenomic studies
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2013-01-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00063895

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Phase 1

Completed

Conditions: Post-transplant Lymphoproliferative Disorder
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Stage III Adult Burkitt Lymphoma
Stage III Adult Diffuse Large Cell Lymphoma
Stage IV Adult Burkitt Lymphoma
Stage IV Adult Diffuse Large Cell Lymphoma
Waldenström Macroglobulinemia

Interventions: Biological: rituximab
Radiation: indium In 111 ibritumomab tiuxetan
Radiation: yttrium Y 90 ibritumomab tiuxetan

First Posted Date: 2003-07-09

Last Posted Date: 2013-01-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT00064246

Locations: 🇺🇸
AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

Phase 1

Completed

Conditions: Lip and Oral Cavity Cancer
Oropharyngeal Cancer
Stage 0 Lip and Oral Cavity Cancer
Stage 0 Oropharyngeal Cancer
Tongue Cancer

Interventions: Biological: Ad5CMV-p53 gene
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00064103

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy